专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20080118549A1 SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES 有权
标题翻译：可持续发布的内窥镜植入物和治疗卵巢血管病的方法
公开(公告)号：US20080118549A1
公开(公告)日：2008-05-22
申请号：US12024017
申请日：2008-01-31
申请人： Glenn HUANG , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
发明人： Glenn HUANG , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
IPC分类号： A61K9/00 , A61K31/502 , A61P27/16
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
摘要翻译：生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。植入物可以放置在眼睛中以治疗一种或多种眼部病症，例如眼睛血管病变或青光眼等。

32. 发明申请

US20080118548A1 SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES 有权
公开(公告)号：US20080118548A1
公开(公告)日：2008-05-22
申请号：US12024014
申请日：2008-01-31
申请人： Glenn HUANG , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
发明人： Glenn HUANG , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
IPC分类号： A61K9/00 , A61P27/16
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

33. 发明申请

US20080118547A1 SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR TREATING OCULAR VASCULOPATHIES 有权
公开(公告)号：US20080118547A1
公开(公告)日：2008-05-22
申请号：US12024010
申请日：2008-01-31
申请人： Glenn Huang , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
发明人： Glenn Huang , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
IPC分类号： A61K9/00
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

34. 发明申请

US20070148208A1 ANTI-EXCITITOXIC SUSTAINED RELEASE INTRACULAR IMPLANTS AND RELATED METHODS 审中-公开
标题翻译：抗真菌持续释放入侵植入物及相关方法
公开(公告)号：US20070148208A1
公开(公告)日：2007-06-28
申请号：US11680615
申请日：2007-02-28
申请人： Patrick Hughes , James Burke , Rhett Schiffman
发明人： Patrick Hughes , James Burke , Rhett Schiffman
IPC分类号： A61F2/02 , A61K31/13
CPC分类号： A61K9/0051
摘要： Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
摘要翻译：生物相容性眼内植入物包括抗兴奋性毒性剂和可生物降解的聚合物，其有效促进抗兴奋性毒性剂长时间释放到眼睛中。植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变。

35. 发明申请

US20060257452A1 Ocular therapy using alpha-2 adrenergic receptor anterior compounds having enhanced clearance rates 有权
标题翻译：使用具有增强的清除率的α-2肾上腺素能受体前体化合物进行眼部治疗
公开(公告)号：US20060257452A1
公开(公告)日：2006-11-16
申请号：US11416929
申请日：2006-05-02
申请人： Patrick Hughes , James Burke , Joan-En Chang-Lin
发明人： Patrick Hughes , James Burke , Joan-En Chang-Lin
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K9/0048 , A61K9/1647
摘要： Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
摘要翻译：眼科治疗材料，例如含液组合物和聚合物药物递送系统，包括治疗成分，其包括α2肾上腺素能受体激动剂，其从施用该物质的个体眼睛的前段清除。 α2肾上腺素能受体激动剂可具有大于约3小时的玻璃体半衰期。本发明的材料可有效治疗影响眼前段或眼部前段和后段的眼睛状况。这些材料适用于玻璃体内或眼周内给药，并且可以为已经施用材料的患者提供延长的药物递送和治疗益处。 α2肾上腺素能受体激动剂可以在含液制剂和/或生物可侵蚀和/或非生物可侵蚀的聚合物植入物和微粒中提供。还描述了制备和使用本发明材料的方法。

36. 发明申请

US20060173060A1 Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems 有权
公开(公告)号：US20060173060A1
公开(公告)日：2006-08-03
申请号：US11395019
申请日：2006-03-31
申请人： James Chang , Patrick Hughes
发明人： James Chang , Patrick Hughes
IPC分类号： A61K31/4166 , A61K9/50 , A61K9/16
CPC分类号： A61K31/4166
摘要： Biocompatible microparticles include an ophthalmically active alpha-2 adrenergic receptor agonist and a biodegradable polymer. The microparticles include oil-in-water emulsified microparticles which can be used to treat an ocular condition, such as glaucoma.

37. 发明申请

US20050244477A1 Tyrosine kinase microsphers 有权
标题翻译：酪氨酸激酶微球
公开(公告)号：US20050244477A1
公开(公告)日：2005-11-03
申请号：US11119463
申请日：2005-04-29
申请人： Patrick Hughes , Christian Sarrazin , Elisabeth Rossi , Michele Boix
发明人： Patrick Hughes , Christian Sarrazin , Elisabeth Rossi , Michele Boix
IPC分类号： A61K9/00 , A61K9/20 , A61K31/00 , A61K31/404 , A61F2/00
CPC分类号： A61K9/0051 , A61K9/1647 , Y10T428/2985
摘要： Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.
摘要翻译：生物相容性眼内微球包括酪氨酸激酶抑制剂和可生物降解的聚合物，其有效促进酪氨酸激酶抑制剂延长一段时间后进入眼睛玻璃体。微球的治疗剂可以与可生物降解的聚合物基质相结合，例如基本上不含聚乙烯醇的基质。微球可以放置在眼睛中以治疗或减少一种或多种眼睛病症的发生。

38. 发明申请

US20050244473A1 Memantine intravitreal implants 审中-公开
标题翻译：美金刚玻璃体内植入物
公开(公告)号：US20050244473A1
公开(公告)日：2005-11-03
申请号：US11117879
申请日：2005-04-29
申请人： Patrick Hughes , Lon Spada , Hiroshi Sugimoto , Wendy Blanda , James Chang
发明人： Patrick Hughes , Lon Spada , Hiroshi Sugimoto , Wendy Blanda , James Chang
IPC分类号： A61K9/00 , A61K31/13 , A61F2/00
CPC分类号： A61K9/0051
摘要： Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
摘要翻译：生物相容性眼内植入物包括抗兴奋性毒性剂和可生物降解的聚合物，其有效促进抗兴奋性毒性剂长时间释放到眼睛中。植入物的治疗剂可以与可生物降解的聚合物基质相关，例如基本上不含聚乙烯醇的基质。植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变。

39. 发明申请

US20050244472A1 Intraocular drug delivery systems containing excipients with reduced toxicity and related methods 审中-公开
标题翻译：含有降低毒性的赋形剂和相关方法的眼内药物递送系统
公开(公告)号：US20050244472A1
公开(公告)日：2005-11-03
申请号：US11092122
申请日：2005-03-28
申请人： Patrick Hughes , Laurent Delahaye , Michele Boix
发明人： Patrick Hughes , Laurent Delahaye , Michele Boix
IPC分类号： A61F2/00 , A61F9/00 , A61K9/00 , A61K9/16 , A61K31/724 , A61K39/395 , A61K47/34 , A61K47/40 , A61K47/48 , A61K48/00
CPC分类号： A61K9/0051 , A61F9/0008 , A61F9/0017 , A61K9/1647 , A61K31/724 , A61K47/34 , A61K47/40
摘要： Drug delivery systems suitable for administration into the interior of an eye of a person or animal are described. The present systems include one or more components which are effective in improving a release profile of a drug from the system, improving the stability of the drug, and improving the ocular tolerability of the drug. The present systems include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and an excipient component with reduced toxicity to retinal cells. The excipient component may include a cyclodextrin component that may be complexed with the therapeutic agents to provide advantages over existing intraocular drug delivery systems. The cyclodextrin component of the present systems have a reduced toxicity relative to benzyl alcohol or polysorbate 80. The drug delivery systems include one or more drug delivery elements such as microparticles, bioerodible implants, non-bioerodible implants, and combinations thereof. Methods of using and producing the drug delivery systems are also described.
摘要翻译：描述了适合施用于人或动物的眼睛内部的药物递送系统。本发明的系统包括一种或多种有效改善药物从系统释放曲线，提高药物稳定性和改善药物的眼睛耐受性的成分。本发明的系统包括当放置在眼睛中时有效提供所需治疗效果的量的一种或多种治疗剂和对视网膜细胞毒性降低的赋形剂组分。赋形剂组分可以包括可与治疗剂复合的环糊精组分，以提供优于现有的眼内药物递送系统的优点。本系统的环糊精组分相对于苯甲醇或聚山梨酸酯80具有降低的毒性。药物递送系统包括一种或多种药物递送元件，例如微粒，生物侵蚀性植入物，非生物侵蚀性植入物及其组合。还描述了使用和产生药物递送系统的方法。

40. 发明申请

US20050244463A1 Sustained release intraocular implants and methods for treating ocular vasculopathies 审中-公开
标题翻译：持续释放眼内植入物和治疗眼血管病变的方法
公开(公告)号：US20050244463A1
公开(公告)日：2005-11-03
申请号：US10836911
申请日：2004-04-30
申请人： Glenn Huang , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
发明人： Glenn Huang , Brittany Jackson , James Burke , Ton Lin , Patrick Hughes , Larry Wheeler , Rosy Donn
IPC分类号： A61K9/00 , A61K31/498
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
摘要翻译：生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。植入物可以放置在眼睛中以治疗一种或多种眼部病症，例如眼睛血管病变或青光眼等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式